Core Viewpoint - Inspira Technologies is positioning itself to enter the multi-billion dollar liquid biopsy diagnostics market through a proposed acquisition and a strategic equity investment of $15 million, while ensuring protections for existing shareholders [1][2]. Equity Investment - The proposed transaction includes a $15 million equity investment at a premium to the current market capitalization, based on a pre-money valuation of $180 million, reflecting the strategic investor's assessment of the liquid biopsy technology's potential [3]. - The identity of the strategic investor will be disclosed after shareholder approval and execution of definitive agreements, with $12 million of the investment proceeds allocated to fund existing technologies [4]. Strategic Acquisition - The acquisition involves an advanced liquid biopsy diagnostics business, allowing Inspira to enter the growing liquid biopsy market with a proprietary platform designed for cancer characterization [5]. - The platform has shown high concordance with traditional tissue biopsy in clinical studies, indicating its potential to provide valuable diagnostic insights [5][6]. - The initial clinical focus of the platform is on breast cancer, with a projected global liquid biopsy market size of approximately $58 billion over the next decade [6]. Regulatory Pathway - Following the acquisition, the company plans to pursue FDA clearance for the liquid biopsy platform through the 510(k) regulatory pathway, leveraging existing regulatory precedents [7]. - An existing reimbursement code is already in place for the intended clinical use, facilitating a clear path to reimbursement upon regulatory clearance [8]. Shareholder Protection Framework - The transaction includes a shareholder protection framework to preserve the economic upside of existing technologies for current shareholders while allowing participation in the growth potential of the liquid biopsy platform [9]. - Existing shareholders are expected to receive contingent value rights, ensuring that future realizations of value from respiratory technology assets are allocated exclusively to them [9]. Company Overview - Inspira Technologies specializes in advanced respiratory support and real-time blood monitoring solutions, with FDA-cleared products and a growing IP portfolio [10].

Core Viewpoint - Inspira Technologies has announced a proposed two-part transaction involving the acquisition of a liquid biopsy diagnostics business and a concurrent $15 million strategic equity investment, aimed at expanding into the high-growth diagnostics market [1][2]. Equity Investment - The transaction includes a $15 million equity investment at a premium to the current market capitalization, based on a pre-money valuation of $180 million, reflecting the strategic investor's assessment of the liquid biopsy technology's value [3]. - The identity of the strategic investor will be disclosed after shareholder approval and execution of definitive agreements, with $12 million of the investment proceeds allocated to fund existing respiratory and blood monitoring technologies [4]. Strategic Acquisition - The acquisition involves an advanced liquid biopsy diagnostics business through an all-share transaction, allowing entry into the growing liquid biopsy market with a proprietary platform designed for cancer characterization [5]. - The platform has shown high concordance with traditional tissue biopsy in clinical validation studies, indicating its potential to provide meaningful diagnostic insights [5][6]. - The initial clinical focus of the platform is on breast cancer, with applicability across other oncology indications, and the global liquid biopsy market is projected to reach approximately $58 billion in the next decade [6]. Regulatory Pathway - Following the acquisition, the company plans to pursue FDA clearance for the liquid biopsy platform through the 510(k) regulatory pathway, leveraging existing reimbursement codes for intended clinical use [7]. Shareholder Protection Framework - The transaction includes a shareholder protection framework to preserve the economic upside of existing respiratory and blood-monitoring platforms for current shareholders while allowing participation in the growth potential of the liquid biopsy platform [9].

RA'ANANA, Israel, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) ("Inspira" or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today reaffirmed its previously announced binding purchase orders totaling $49.5 million and provided an update on execution timing, noting that payment activity has been structured to commence with the 2026 fiscal cycle, in alignment with immediate regulatory sequencing and phased deployment milestones.The Com ...

Revenues Relating to the Binding Purchase Orders Expected to be Received and Recognized in 2026RA'ANANA, Israel, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ("Inspira" or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today reaffirmed its previously announced binding purchase orders totaling $49.5 million and provided an update on execution timing, noting that payment activity has been structured to commence with the 2026 fiscal c ...

Core Viewpoint - Inspira Technologies has announced a registered direct offering of ordinary shares and a Standby Equity Purchase Agreement (SEPA) to enhance its financial flexibility and support its strategic initiatives [1][4][7]. Group 1: Registered Direct Offering - The company will issue and sell 1,565,217 ordinary shares at a price of $1.15 per share, generating gross proceeds of approximately $1.8 million [2][9]. - The offering is expected to close on or about December 16, 2025, pending customary closing conditions [2]. Group 2: Standby Equity Purchase Agreement (SEPA) - The SEPA allows the company to sell up to $25 million of its ordinary shares over a 36-month period at its discretion, without any minimum purchase requirements [4][9]. - The company is not obligated to utilize this facility, providing it with opportunistic capital raising options as needed [4][9]. Group 3: Use of Proceeds - The net proceeds from the registered direct offering and any future proceeds from the SEPA will be used for working capital and general corporate purposes, specifically to support the company's strategic roadmap and planned operations [6][9]. Group 4: Company Overview - Inspira Technologies is a commercial-stage medical device company specializing in advanced respiratory support and real-time blood monitoring solutions, with FDA-cleared products and a growing intellectual property portfolio [8][10].

RA'ANANA, Israel, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN, IINNW)) ("Inspira," "Inspira Technologies," or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced that it has entered into a definitive agreement with YA II PN, Ltd. ("YA") for a registered direct offering of its ordinary shares, and has also entered into a Standby Equity Purchase Agreement ("SEPA") with YA providing additional equity financing flexibility.In ...

Core Viewpoint - Inspira Technologies has secured a significant patent for its Convertible Dual Lumen Cannula device in Japan, enhancing its market position in the medical device sector and supporting future commercialization efforts [1][2]. Group 1: Patent and Market Position - The Japan Patent Office granted Patent No. 7777598, providing Inspira exclusive commercial rights for the Dual Lumen Cannula technology in Japan until 2041 [2]. - This patent complements an existing U.S. Patent granted in 2023, creating a protective barrier across two major healthcare markets [2]. - The patented technology allows a single-lumen cannula to convert into a dual-lumen cannula intravascularly, which may reduce infection risks and procedural complications compared to traditional solutions [3]. Group 2: Product and Strategic Implications - The Convertible Dual Lumen Cannula is designed to be a high-value disposable product, potentially enhancing patient safety and procedural efficiency while being more affordable than traditional dual-lumen cannulas [4]. - The company is positioned to benefit from both its respiratory support platforms and future disposable revenue streams due to the proprietary protection in the U.S. and Japan [4]. - Inspira Technologies is advancing its product offerings, including the INSPIRA™ ART100 system for cardiopulmonary bypass and the next-generation INSPIRA ART500 system, which aims to deliver oxygenation while patients remain awake [5].

RA'ANANA, Israel, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) ("Inspira," "Inspira Technologies," or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced a strategic expansion of its core blood laboratory capabilities, marking a substantial step in the Company's evolution into a broader cutting edge technologies, positioning it for accelerated future growth.The strategic expansion includes transitioning to a substantially ...

Core Insights - Inspira Technologies is expanding its blood laboratory capabilities, transitioning to a larger, state-of-the-art facility to support its growth in blood-based clinical diagnostics and next-generation blood-analysis technologies [1][2][4] Group 1: Strategic Expansion - The strategic expansion includes moving to a larger laboratory, increasing recruitment of specialized personnel, upgrading research instrumentation, and expanding operational capacity [2][3] - The upgraded facility is expected to significantly increase sample processing capacity and integrate advanced capabilities throughout the laboratory [3] Group 2: Commitment to Innovation - This upgrade aims to provide the foundation for Inspira's commitment to innovation, targeting high-value underserved medical needs [4] - The CTO of Inspira Technologies emphasized that this expansion enhances execution capacity and accelerates development, positioning the company for aggressive business growth [5] Group 3: Company Overview - Inspira Technologies specializes in advanced respiratory support and real-time blood monitoring solutions, with FDA-cleared products like the INSPIRA™ ART100 system and the upcoming INSPIRA ART500 system [6] - The company is advancing its proprietary blood sensor platform, HYLA™, and is increasingly positioned as an attractive platform within the life-support and MedTech landscape [6]

Core Insights - Inspira Technologies has completed the regulatory submission of its FDA-cleared INSPIRA™ ART100 system to the UAE Ministry of Health and Prevention, with final approval expected imminently, marking a significant step towards commercial entry into the Gulf region [1][2][3] Company Overview - Inspira Technologies is a commercial-stage medical device company specializing in advanced respiratory support and real-time blood monitoring solutions, with the INSPIRA™ ART100 system approved for cardiopulmonary bypass in the U.S. and ECMO procedures outside the U.S. [4] - The company is also developing the INSPIRA ART500, a next-generation system designed for oxygenation while patients remain awake and spontaneously breathing, alongside advancing the HYLA™ blood sensor platform for continuous, non-invasive monitoring [4] Regulatory and Market Strategy - The regulatory milestone follows high-level discussions in the UAE, laying the groundwork for potential nationwide deployment and clinical integration of the ART100 system post-approval [2][3] - The UAE is recognized for its efficient and innovation-driven regulatory framework, which is expected to enhance Inspira's regional partnerships and unlock broad commercialization potential across the UAE's healthcare networks [3]